Lyons Gary A
SEC-identified person · CIK 1123343 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Neurocrine Biosciences INC NBIX | Director · President and CEO | filed 2006 - 2026 |
| Travere Therapeutics, Inc. TVTX | Director | filed 2014 - 2026 |
| Rigel Pharmaceuticals INC RIGL | Director | filed 2006 - 2023 |
| Tokai Pharmaceuticals Inc TKAI | Director | filed 2017 - 2023 |
| Vical INC VICl | Director | filed 2006 - 2022 |
| Plus Therapeutics, INC. PSTV | Director | filed 2013 - 2018 |
| Kalobios Pharmaceuticals INC KBIOQ | Director | filed 2012 - 2015 |
| Neurogesx Inc NGSX | Director | filed 2011 - 2012 |
| Poniard Pharmaceuticals, INC. PARD | Director | filed 2009 - 2011 |
| Facet Biotech Corp FACT | Director | filed 2008 - 2010 |
| Protein Design Labs INC/DE pdli | Director | filed 2008 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.